Phenotypic differences between esophageal and gastric intestinal metaplasia

Modern Pathology

Volumn 17, Issue 1, 2004, Pages 62-74

  Piazuelo, M Blanca ^a   Haque, Salima ^b   Delgado, Alberto ^a   Du, Joanna X ^a   Rodriguez, Fred ^a,c   Correa, Pelayo ^a  

^a LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Barrett's esophagus; Cyclooxygenase 2; Cytokeratins; Das 1; Gastric intestinal metaplasia; Inducible nitric oxide synthase; Ki 67; Mucins

Indexed keywords

CYCLOOXYGENASE 2; CYTOKERATIN 20; CYTOKERATIN 7; INDUCIBLE NITRIC OXIDE SYNTHASE; MUCIN 1; MUCIN 2; MUCIN 5AC; SULFOMUCIN;

ADULT; ARTICLE; BARRETT ESOPHAGUS; CELL DIFFERENTIATION; CELL PROLIFERATION; CONTROLLED STUDY; ESOPHAGUS BIOPSY; ESOPHAGUS CANCER; HELICOBACTER PYLORI; HISTOCHEMISTRY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFLAMMATION; INTESTINE BIOPSY; MAJOR CLINICAL STUDY; METAPLASIA; MORPHOLOGY; PHENOTYPE; PRIORITY JOURNAL; STOMACH CANCER;

AGED; ANTIBODIES; BARRETT ESOPHAGUS; CA-15-3 ANTIGEN; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; CYCLOOXYGENASE 2; ESOPHAGEAL NEOPLASMS; ESOPHAGUS; FEMALE; HELICOBACTER PYLORI; HUMANS; IMMUNOHISTOCHEMISTRY; INFLAMMATION MEDIATORS; KERATIN-20; KERATIN-7; LOUISIANA; MALE; METAPLASIA; MIDDLE AGED; MUCINS; NITRIC OXIDE SYNTHASE TYPE II; PHENOTYPE; PRECANCEROUS CONDITIONS; STAINING AND LABELING; STOMACH; STOMACH NEOPLASMS;

EID: 3042602815     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.3800016     Document Type: Article

References (92)

1. Parkin DM, Bray FI, Devesa SS. Cancer burden in the year 2000. The global picture. Eur J Cancer 2001;37(Suppl 8):S4-S66.
2. Parkin DM, Bray FI, Devesa SS. Corrigendum to 'Cancer burden in the year 2000. The global picture' [Eur J Cancer (2001) 37(Suppl 8) S4-S66]. Eur J Cancer 2003;39:848.
3. Bytzer P, Christensen PB, Damkier P, et al. Adenocarcinoma of the esophagus and Barrett's esophagus: a population-based study. Am J Gastroenterol 1999;94:86-91.
4. Devesa SS, Blot WJ, Fraumeni Jr JF. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 1998;83:2049-2053.
5. Newnham A, Quinn MJ, Babb P, et al. Trends in the subsite and morphology of oesophageal and gastric cancer in England and Wales 1971-1998. Aliment Pharmacol Ther 2003;17:665-676.
6. Pera M, Pera M. Recent changes in the epidemiology of esophageal cancer. Surg Oncol 2001;10:81-90.
7. El Serag HB, Mason AC, Petersen N, et al. Epidemiological differences between adenocarcinoma of the oesophagus and adenocarcinoma of the gastric cardia in the USA. Gut 2002;50:368-372.
8. Allison P, Johnstone A. The oesophagus lined with gastric mucous membrane. Thorax 1953;8:87-101.
9. Barrett N. The lower esophagus lined by columnar epithelium. Surgery 1957;41:881-894.
10. Paull A, Trier JS, Dalton MD, et al. The histologic spectrum of Barrett's esophagus. N Engl J Med 1976;295:476-480.
11. Goldblum JR. Barrett's esophagus and Barrett's-related dysplasia. Mod Pathol 2003;16:316-324.
12. Sampliner RE. Updated guidelines for the diagnosis, surveillance, and therapy of Barrett's esophagus. Am J Gastroenterol 2002;97:1888-1895.
13. Cameron AJ, Ott BJ, Payne WS. The incidence of adenocarcinoma in columnar-lined (Barrett's) esophagus. N Engl J Med 1985;313:857-859.
14. Correa P, Haenszel W, Cuello C, et al. A model for gastric cancer epidemiology. Lancet 1975;2:58-60.
15. Correa P. A human model of gastric carcinogenesis. Cancer Res 1988;48:3554-3560.
16. Filipe MI, Munoz N, Matko I, et al. Intestinal metaplasia types and the risk of gastric cancer: a cohort study in Slovenia. Int J Cancer 1994;57:324-329.
17. Haggitt RC. Barrett's esophagus, dysplasia, and adenocarcinoma. Hum Pathol 1994;25:982-993.
18. Ruol A, Parenti A, Zaninotto G, et al. Intestinal metaplasia is the probable common precursor of adenocarcinoma in Barrett's esophagus and adenocarcinoma of the gastric cardia. Cancer 2000;88:2520-2528.
19. You WC, Li JY, Blot WJ, et al. Evolution of precancerous lesions in a rural Chinese population at high risk of gastric cancer. Int J Cancer 1999;83:615-619.
20. Dekker J, Rossen JW, Buller HA, et al. The MUC family: an obituary. Trends Biochem Sci 2002;27:126-131.
21. Jass JR. Mucins in the gastrointestinal tract: their role in the pathogenesis and as diagnostic markers. Annual Meeting of the United States and Canadian Academy of Pathology. March 22-28 2003.
22. Arul GS, Moorghen M, Myerscough N, et al. Mucin gene expression in Barrett's oesophagus: an in situ hybridisation and immunohistochemical study. Gut 2000;47:753-761.
23. Carrato C, Balague C, de Bolos C, et al. Differential apomucin expression in normal and neoplastic human gastrointestinal tissues. Gastroenterology 1994;107:160-172.
24. Guillem P, Billeret V, Buisine MP, et al. Mucin gene expression and cell differentiation in human normal, premalignant and malignant esophagus. Int J Cancer 2000;88:856-861.
25. Reis CA, David L, Correa P, et al. Intestinal metaplasia of human stomach displays distinct patterns of mucin (MUC1, MUC2, MUC5AC, and MUC6) expression. Cancer Res 1999;59:1003-1007.
26. Reis CA, David L, Carvalho F, et al. Immunohistochemical study of the expression of MUC6 mucin and co-expression of other secreted mucins (MUC5AC and MUC2) in human gastric carcinomas. J Histochem Cytochem 2000;48:377-388.
27. Chinyama CN, Marshall RE, Owen WJ, et al. Expression of MUC1 and MUC2 mucin gene products in Barrett's metaplasia, dysplasia and adenocarcinoma: an immunopathological study with clinical correlation. Histopathology 1999;35:517-524.
28. Warson C, Van De Bovenkamp JH, Korteland-Van Male AM, et al. Barrett's esophagus is characterized by expression of gastric-type mucins (MUC5AC, MUC6) and TFF peptides (TFF1 and TFF2), but the risk of carcinoma development may be indicated by the intestinal-type mucin, MUC2. Hum Pathol 2002;33:660-668.
29. Silva E, Teixeira A, David L, et al. Mucins as key molecules for the classification of intestinal metaplasia of the stomach. Virchows Arch 2002;440:311-317.
30. Teixeira A, David L, Reis CA, et al. Expression of mucins (MUC1, MUC2, MUC5AC, and MUC6) and type 1 Lewis antigens in cases with and without Helicobacter pylori colonization in metaplastic glands of the human stomach. J Pathol 2002;197:37-43.
31. Lee HS, Lee HK, Kim HS, et al. MUC1, MUC2, MUC5AC, and MUC6 expressions in gastric carcinomas: their roles as prognostic indicators. Cancer 2001;92:1427-1434.
32. Pinto-de-Sousa J, David L, Reis CA, et al. Mucins MUC1, MUC2, MUC5AC and MUC6 expression in the evaluation of differentiation and clinico-biological behaviour of gastric carcinoma. Virchows Arch 2002;440:304-310.
33. Das KM, Sakamaki S, Vecchi M, et al. The production and characterization of monoclonal antibodies to a human colonic antigen associated with ulcerative colitis: cellular localization of the antigen by using the monoclonal antibody. J Immunol 1987;139:77-84.
34. Kesari KV, Yoshizaki N, Geng X, et al. Externalization of tropomyosin isoform 5 in colon epithelial cells. Clin Exp Immunol 1999;118:219-227.
35. Das KM, Prasad I, Garla S, et al. Detection of a shared colon epithelial epitope on Barrett epithelium by a novel monoclonal antibody. Ann Intern Med 1994;120:753-756.
36. DeMeester SR, Wickramasinghe KS, Lord RV, et al. Cytokeratin and DAS-1 immunostaining reveal similarities among cardiac mucosa, CIM, and Barrett's esophagus. Am J Gastroenterol 2002;97:2514-2523.
37. Glickman JN, Wang H, Das KM, et al. Phenotype of Barrett's esophagus and intestinal metaplasia of the distal esophagus and gastroesophageal junction: an immunohistochemical study of cytokeratins 7 and 20, Das-1 and 45 MI. Am J Surg Pathol 2001;25:87-94.
38. Das K, Slate J, Ramsundar L. Gastric intestinal metaplasia with colonic phenotype, as detected by a novel biomarker, mAb Das-1, is highly associated with gastric carcinoma. Gastroenterology 2000;118:A273 [abstract].
39. Moll R, Franke WW, Schiller DL, et al. The catalog of human cytokeratins: patterns of expression in normal epithelia, tumors and cultured cells. Cell 1982;31:11-24.
40. Moll R, Schiller DL, Franke WW. Identification of protein IT of the intestinal cytoskeleton as a novel type I cytokeratin with unusual properties and expression patterns. J Cell Biol 1990;111:567-580.
41. Ormsby AH, Goldblum JR, Rice TW, et al. Cytokeratin subsets can reliably distinguish Barrett's esophagus from intestinal metaplasia of the stomach. Hum Pathol 1999;30:288-294.
42. Kirchner T, Muller S, Hattori T, et al. Metaplasia, intraepithelial neoplasia and early cancer of the stomach are related to dedifferentiated epithelial cells defined by cytokeratin-7 expression in gastritis. Virchows Arch 2001;439:512-522.
43. Stosiek P, Brautigam E, Kasper M. Expression of cytokeratin 7 in human glandular epithelium of fetal stomach. Acta Histochem 1991;91:21-23.
44. Moll R, Lowe A, Laufer J, et al. Cytokeratin 20 in human carcinomas. A new histodiagnostic marker detected by monoclonal antibodies. Am J Pathol 1992;140:427-447.
45. Jovanovic I, Tzardi M, Mouzas IA, et al. Changing pattern of cytokeratin 7 and 20 expression from normal epithelium to intestinal metaplasia of the gastric mucosa and gastroesophageal junction. Histol Histopathol 2002;17:445-454.
46. Ormsby AH, Goldblum JR, Rice TW, et al. The utility of cytokeratin subsets in distinguishing Barrett's-related oesophageal adenocarcinoma from gastric adenocarcinoma. Histopathology 2001;38:307-311.
47. Park SY, Kim HS, Hong EK, et al. Expression of cytokeratins 7 and 20 in primary carcinomas of the stomach and colorectum and their value in the differential diagnosis of metastatic carcinomas to the ovary. Hum Pathol 2002;33:1078-1085.
48. El Zimaity HM, Graham DY. Cytokeratin subsets for distinguishing Barrett's esophagus from intestinal metaplasia in the cardia using endoscopic biopsy specimens. Am J Gastroenterol 2001;96:1378-1382.
49. Wilson KT. Angiogenic markers, neovascularization and malignant deformation of Barrett's esophagus. Dis Esophagus 2002;15:16-21.
50. Cheong E, Igali L, Harvey I, et al. Cyclo-oxygenase-2 expression in Barrett's oesophageal carcinogenesis: an immunohistochemical study. Aliment Pharmacol Ther 2003;17:379-386.
51. Morris CD, Armstrong GR, Bigley G, et al. Cyclooxygenase-2 expression in the Barrett's metaplasia-dysplasia-adenocarcinoma sequence. Am J Gastroenterol 2001;96:990-996.
52. Rajnakova A, Moochhala S, Goh PM, et al. Expression of nitric oxide synthase, cyclooxygenase, and p53 in different stages of human gastric cancer. Cancer Lett 2001;172:177-185.
53. Son HJ, Kim YH, Park DI, et al. Interaction between cyclooxygenase-2 and inducible nitric oxide synthase in gastric cancer. J Clin Gastroenterol 2001;33:383-388.
54. Wilson KT, Fu S, Ramanujam KS, et al. Increased expression of inducible nitric oxide synthase and cyclooxygenase-2 in Barrett's esophagus and associated adenocarcinomas. Cancer Res 1998;58:2929-2934.
55. Yamagata R, Shimoyama T, Fukuda S, et al. Cyclooxygenase-2 expression is increased in early intestinal-type gastric cancer and gastric mucosa with intestinal metaplasia. Eur J Gastroenterol Hepatol 2002;14:359-363.
56. Gerdes J, Schwab U, Lemke H, et al. Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer 1983;31:13-20.
57. Schmidt MH, Broll R, Bruch HP, et al. The proliferation marker pKi-67 organizes the nucleolus during the cell cycle depending on Ran and cyclin B. J Pathol 2003;199:18-27.
58. Hong MK, Laskin WB, Herman BE, et al. Expansion of the Ki-67 proliferative compartment correlates with degree of dysplasia in Barrett's esophagus. Cancer 1995;75:423-429.
59. Ishida M, Gomyo Y, Tatebe S, et al. Apoptosis in human gastric mucosa, chronic gastritis, dysplasia and carcinoma: analysis by terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick end labelling. Virchows Arch 1996;428:229-235.
60. Miracco C, Spina D, Vindigni C, et al. Cell proliferation patterns and p53 expression in gastric dysplasia. Int J Cancer 1995;62:149-154.
61. Whittles CE, Biddlestone LR, Burton A, et al. Apoptotic and proliferative activity in the neoplastic progression of Barrett's oesophagus: a comparative study. J Pathol 1999;187:535-540.
62. Prophet E, Mills B, Arrington J, et al. Laboratory Methods in Histotechnology. Washington, DC: American Registry of Pathology, 1994.
63. Spicer S. Diamine methods for differentiating mucosubstances histochemically. J Histochem Cytochem 1965;8:211-234.
64. Garvey W, Fathi A, Bigelow F. Modified Steiner for the demonstration of spirochetes. J Histotechnol 1985;8:15-17.
65. Taylor-Papadimitriou J, Peterson JA, Arklie J, et al. Monoclonal antibodies to epithelium-specific components of the human milk fat globule membrane: production and reaction with cells in culture. Int J Cancer 1981;28:17-21.
66. Riddell RH, Goldman H, Ransohoff DF, et al. Dysplasia in inflammatory bowel disease: standardized classification with provisional clinical applications. Hum Pathol 1983;14:931-968.
67. Rugge M, Correa P, Dixon MF, et al. Gastric dysplasia: the Padova international classification. Am J Surg Pathol 2000;24:167-176.
68. Correa P, Haenszel W, Cuello C, et al. Gastric precancerous process in a high risk population: cohort follow-up. Cancer Res 1990;50:4737-4740.
69. Correa P, Haenszel W, Cuello C, et al. Gastric precancerous process in a high risk population: cross-sectional studies. Cancer Res 1990;50:4731-4736.
70. Matsukura N, Suzuki K, Kawachi T, et al. Distribution of marker enzymes and mucin in intestinal metaplasia in human stomach and relation to complete and incomplete types of intestinal metaplasia to minute gastric carcinomas. J Natl Cancer Inst 1980;65:231-240.
71. Teglbjaerg PS, Nielsen HO. 'Small intestinal type' and 'colonic type' intestinal metaplasia of the human stomach, and their relationship to the histogenetic types of gastric adenocarcinoma. Acta Pathol Microbiol Scand [A] 1978;86A:351-355.
72. Heilmann KL, Hopker WW. Loss of differentiation in intestinal metaplasia in cancerous stomachs. A comparative morphologic study. Pathol Res Pract 1979;164:249-258.
73. Dixon MF, Genta RM, Yardley JH, et al. Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol 1996;20:1161-1181.
74. Silva S, Filipe MI, Pinho A. Variants of intestinal metaplasia in the evolution of chronic atrophic gastritis and gastric ulcer. A follow up study. Gut 1990;31:1097-1104.
75. Rokkas T, Filipe MI, Sladen GE. Detection of an increased incidence of early gastric cancer in patients with intestinal metaplasia type III who are closely followed up. Gut 1991;32:1110-1113.
76. Jass JR. Mucin histochemistry of the columnar epithelium of the oesophagus: a retrospective study. J Clin Pathol 1981;34:866-870.
77. Tosi P, Filipe MI, Luzi P, et al. Gastric intestinal metaplasia type III cases are classified as low-grade dysplasia on the basis of morphometry. J Pathol 1993;169:73-78.
78. Kelley JR, Duggan JM. Gastric cancer epidemiology and risk factors. J Clin Epidemiol 2003;56:1-9.
79. Dixon MF, Neville PM, Mapstone NP, et al. Bile reflux gastritis and Barrett's oesophagus: further evidence of a role for duodenogastro-oesophageal reflux? Gut 2001;49:359-363.
80. Zaninotto G, Portale G, Parenti A, et al. Role of acid and bile reflux in development of specialised intestinal metaplasia in distal oesophagus. Dig Liver Dis 2002;34:251-257.
81. Farinati F, Cardin R, Russo VM. Helicobacter pylori CagA status, mucosal oxidative damage and gastritis phenotype: a potential pathway to cancer? Helicobacter 2003;8:227-234.
82. Pignatelli B, Bancel B, Esteve J, et al. Inducible nitric oxide synthase, anti-oxidant enzymes and Helicobacter pylori infection in gastritis and gastric precancerous lesions in humans. Eur J Cancer Prev 1998;7:439-447.
83. Kaur BS, Triadafilopoulos G. Acid- and bile-induced PGE(2) release and hyperproliferation in Barrett's esophagus are COX-2 and PKC-epsilon dependent. Am J Physiol Gastrointest Liver Physiol 2002;283:G327-G334.
84. Richter JE. Importance of bile reflux in Barrett's esophagus. Dig Dis 2000;18:208-216.
85. Petraki K, Mantzaris GJ, Petraki C. Immunohistochemical expression of cytokeratins 7 and 20 in gastric intestinal metaplasia and in Barrett's esophagus. Gastroenterology 2000;118:A226 [abstract].
86. Chu P, Wu E, Weiss LM. Cytokeratin 7 and cytokeratin 20 expression in epithelial neoplasms: a survey of 435 cases. Mod Pathol 2000;13:962-972.
87. Schwerer MJ, Baczako K. Immunohistochemical evaluation of keratin 20 expression in intestinal metaplasia types I to III. J Clin Pathol 1996;49:791-794.
88. Blot WJ, Li JY, Taylor PR, et al. Nutrition intervention trials in Linxian, China: supplementation with specific vitamin/mineral combinations, cancer incidence, and disease-specific mortality in the general population. J Natl Cancer Inst 1993;85:1483-1492.
89. Correa P, Fontham ET, Bravo JC, et al. Chemoprevention of gastric dysplasia: randomized trial of antioxidant supplements and anti-Helicobacter pylori therapy. J Natl Cancer Inst 2000;92:1881-1888.
90. Buttar NS, Wang KK, Anderson MA, et al. The effect of selective cyclooxygenase-2 inhibition in Barrett's esophagus epithelium: an in vitro study. J Natl Cancer Inst 2002;94:422-429.
91. Buttar NS, Wang KK, Leontovich O, et al. Chemoprevention of esophageal adenocarcinoma by COX-2 inhibitors in an animal model of Barrett's esophagus. Gastroenterology 2002;122:1101-1112.
92. Kaur BS, Khamnehei N, Iravani M. Rofecoxib inhibits cyclooxygenase 2 expression and activity and reduces cell proliferation in Barrett's esophagus. Gastroenterology 2002;123:60-67.